Panadol

Small molecule

SSinew Pharma Inc.

Panadol is one of 11 small molecule programs targeting Muscle weakness. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Muscle WeaknessActive, not recruiting

Muscle WeaknessPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Muscle Weakness

#DrugCompanyPhaseTrials

Carnitor

LLeadiant Biosciences, Inc.

Andriol

Ultram

1 4

Neurontin

VViatris Specialty LLC

Phase 3

1 5

Lorcaserin

Eisai

Phase 2

1 6

LY2495655

Eli Lilly

Phase 2

1 7

IMM01-STEM

IImmunis, Inc.

Phase 2

1 8

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

1 9

Botox

RRevance Therapeutics, Inc.

Preclinical

1 10

Esmeron

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acetaminophen1 trial

A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers

Unknown status·SSinew Pharma Inc.·N/A·NCT05563961·48 enrolled

Randomized1 trial

A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study

Completed·SSinew Pharma Inc.·N/A·NCT03451487·28 enrolled

Muscle weakness1 trial

Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction?

Unknown status·HHospital Authority, Hong Kong·Phase 2/3·NCT03496389·30 enrolled

Fever1 trial

A Phase I, Randomised, Open Label, Single Center, Single Oral Dose, Three Treatment, Three Period, Three Sequence, Change-over Bioequivalence Study of Paracetamol Orodispersible Tablet 500 mg (Haleon) to Assess Bioequivalence With Alvedon 500 mg Film-Coated Tablet (Haleon, Sweden) and Panadol 500 mg Film-Coated Tablet (Haleon, Australia) in Healthy Adult Subjects Under Fasting Conditions

Completed·HHALEON·Phase 1·NCT06855576·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Panadol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Panadol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Panadol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinew Pharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SSinew Pharma Inc.

Panadol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acetaminophen1 trial

Randomized1 trial

Muscle weakness1 trial

Fever1 trial

References

Drug Info

Quick Facts

Related News